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This paper focuses on novel approaches in the ﬁeld of nanotechnology-based carriers utilizing ultrasound stimuli as a means to
spatially target gene delivery in vivo, using nanoparticles made with either poly(lactic-co-glycolic acid) (PLGA) or other polymers.
We speciﬁcally discuss the potential for gene delivery by particles that are echogenic (amenable to destruction by ultrasound)
composed either of polymers (PLGA, polystyrene) or other contrast agent materials (Optison, SonoVue microbubbles). The use
of ultrasound is an eﬃcient tool to further enhance gene delivery by PLGA or other echogenic particles in vivo. Echogenic PLGA
nanoparticles are an attractive strategy for ultrasound-mediated gene delivery since this polymer is currently approved by the US
FoodandDrugAdministrationfordrugdeliveryanddiagnosticsincancer,cardiovasculardisease,andalsootherapplicationssuch
as vaccines and tissue engineering. This paper will review recent successes and the potential of applying PLGA nanoparticles for
gene delivery, which include (a) echogenic PLGA used with ultrasound to enhance local gene delivery in tumors or muscle and (b)
PLGA nanoparticles currently under development, which could beneﬁt in the future from ultrasound-enhanced tumor targeted
gene delivery.
1.Introduction
To achieve successful gene therapy in a clinical setting, it is
critical that gene delivery systems be safe and easy to apply
and provide therapeutic transgene expression. Over the past
decades, many studies using viral vectors have established
the gold standard for successful gene transfer and high-level
expression in target cells. However, the upcoming trend is
in the development of improved methods for nonviral gene
transfer, due to the considerable immunogenicity related
to the use of viruses. Nonviral vectors are particularly
suitable since they allow ease of large-scale production
and are relatively less immunogenic. Recently, several novel
nonviral vectors have been developed that approach viruses
with respect to transfection eﬃciency. A variety of nonviral
delivery systems that can be used in diﬀerent clinical
settings are also available and one promising direction is
the development of biodegradable, echogenic nanoparticle
systems that can deliver DNA (or drugs) eﬃciently by the
use of ultrasound-mediated delivery. We will focus our
discussion on PLGA nanoparticles and their promise for
nucleic acid delivery in vivo using ultrasound-mediated gene
delivery methods.
2. Current Sonoporation Principles
A relatively novel strategy for gene and drug delivery
enhancementisapplication ofechogenicnanoparticles made
of poly(d,l-lactic-co-glycolide) (PLGA) or derivatives in
combination with relatively low-intensity ultrasound (US).
This method (referred to as “sonoporation”) can induce
cavitation of or near cellular membranes to enhance delivery
of drugs and nucleic acids in vitro and in vivo. In general,
low-intensity US can induce beneﬁcial and reversible cellular
eﬀects, in contrast to high US intensities, which are more2 Journal of Drug Delivery
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Figure 1: Sonoporation mechanisms for therapeutic delivery. (a) Sonoporation for drug delivery. Drugs can be delivered by sonoporation.
Microbubbleswithdrugattachedtothesurfaceorenclosedwithintheparticletravelincapillaries.UponUSexposureMBsrupture,releasing
the drug contents. Drugs are absorbed by the target tissue. (b) Sonoporation for gene delivery. When plasmid-DNA-(pDNA-) containing
MBs are passed through blood vessels adjacent to tumor cells, US waves rupture MB and release pDNA. Released pDNA penetrates into cells
through their membranes by sonoporation. Reproduced with permission from [5].
likely to induce cellular death. Sonoporation is an emerging
and promising physical method for drug and gene delivery
enhancementinvitroandinvivo[1–4].Infact,sonoporation
has several advantages over other nonphysical techniques
of nucleic acid (DNA, siRNA) delivery including the ability
to also deliver viruses and small molecules (reviewed in
[5]). Sonoporation, however, has some limitations including
penetration depth, some deep (internal) tumors may not
be easily accessible by US, and tissues such as bone might
interfere with the US penetration. Also, the inﬂuence of
air within the lung might also impair the ability of US
waves to penetrate and deliver genes in the lung. Typically,
sonoporation agents (also useful as US contrast agents) can
be composed of micro- or nanoparticles ﬁlled with either
air or gases, which give echogenic properties, surrounded by
a shell of lipids or polymeric formulations. Gas-ﬁlled lipid
particles are called microbubbles (MBs), while echogenic
polymeric particles can be deﬁned as either nanoparticles
(NPs) or microparticles (MPs) depending on their size.
Diﬀerent types of MB have been synthesized by combining
diﬀerent shell compositions such as albumin, galactose,
lipids, or polymers, with diﬀerent gaseous cores such as air,
or high-molecular-weight gases (perﬂuorocarbon, sulphur
hexaﬂuoride, or nitrogen) and several types are available
commercially (reviewed in [5]). This paper will focus on
echogenic NP use in combination with US-mediated sono-
poration to induce gene delivery.
The mechanism of sonoporation involves the motion
of MB or NP and disruption induced by low-intensity US
sonication (Figure 1). US increases the permeability of cell
membranes and the endothelium, thus enhancing thera-
peutic uptake, and can locally increase drug/nucleic acid
transport. Formation of short-lived nanopores (∼100nm)
in the plasma membrane lasts a few seconds and is
implicated as the dominant mechanism associated with
acoustic cavitation [6]. Sonoporation mediates delivery of
drugs and/or nucleic acids that have been incorporated into
or on the surface of nano/microparticles via covalent or
electrostatic interactions, which allow these complexes to
circulate in the blood and retain their cargo until activation
by US. US application results in localized and spatially con-
trolled particle disruption that enhances gene/drug delivery.
Sonoporation-mediated gene delivery has been applied to
date in heart, blood vessels, lung, kidney, muscle, brain,
and tumors with high eﬃciency [7]. However, in order to
provide high transfection eﬃciency, ultrasonic parameters
(suchasacousticpressure,pulselength,dutycycle,repetition
rate, and exposure duration) and nano- or microparticle
properties (such as size and echogenic characteristics of air-
or gas-ﬁlled preparations) should be optimized [7]. The
eﬃciency of drug/gene delivery typically correlates to the
cell location relative to the US (transducer and its proximity
to acoustically active nano- or microparticles). At ∼1MHz
US, echogenic nano/microparticles ormicrobubblesoscillate
steadily. It has been shown that lipid-shelled MB can expand
from 2μmt o∼20–55μm[ 8]. When MBs expand and
collapse near a cell wall, a ﬂuid jet/shock wave is formed
followed by an increase in vascular permeability [9]. In this
manner, drug or nucleic acid transport may occur by con-
vection through a membrane pore [8], and this US-induced
eﬀect may represent the main mechanism for sonoporation-
mediated gene or drug delivery. This is supported by
correlation of the uptake of a dye with cellular deformation
and membrane changes as assessed by scanning electron
microscopy, membrane electrophysiology and atomic force
microscopy [10–12]. Following pore formation, nonspeciﬁc
uptake of extracellular molecules can occur, the membrane
is repaired, and molecules are, therefore, retained within
cells. Mammalian cells have been shown to repair pores of
up to ∼1000μm2 within a short period [13], in a mannerJournal of Drug Delivery 3
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Figure 2: Various nanoparticles (not to scale) that may be used in ultrasound-enhanced drug and gene delivery. (a) Micelle (nonpolymeric)
composed of amphiphilic surfactants. (b) Polymeric micelle composed of amphiphilic block copolymers. (c) Nanoemulsion consisting of a
hydrophobic liquid core stabilized by surfactant. (d) Crystalline nanoparticles. (e) Amorphous polymeric nanoparticle. (f) Condensed ionic
oligomers, such as DNA condensed with PEI or cationic lipids. (g) Single-walled liposome consisting of an amphiphilic bilayer surrounding
an aqueous core. Reprinted with permission from [71].
resembling the kinetics of membrane repair after mechanical
wounding, and Ca2+ levels are thought to promote this re-
sponse [14, 15].
3. Echogenic Nanoparticles
In this paper, nanoparticles (NPs) are deﬁned as molecules
ranging in size from 1nm to 1μm and that are able to
form a separate phase in aqueous suspension. Echogenic
NPs are deﬁned as NPs containing either atmospheric air
or gas to form “nanobubbles” that can be used for drug
a n dg e n ed e l i v e r yw h e nU Si sa p p l i e d .I nm o s tm e d i c a l
applications, NPs typically are in suspension and can be
classiﬁed into micelles, nanoemulsions, and suspensions of
solidnanoparticles(Figure 2).Mostofthemhavebeentested
for US-mediated gene delivery.
3.1. Nanoparticles Used for Gene Delivery
3.1.1. Lipid-Based Nanoparticles. Complexing of cationic
lipids and DNA plasmids (lipofection) is eﬃcient at trans-
fection of various cell lines and several lipid combinations
are available commercially. However, there has been little
combination of US with lipofection, possibly because early
studies using ultrasound and gas bubbles showed that the
addition of the contrast agents enhanced transfection of
naked DNA much more than traditional transfection by
lipofection, which is mediated through endocytosis and
pinocytosis mechanisms [16]. The incubation time of lipo-
fection from transfection to gene expression is also slower
compared to that with naked DNA and contrast agents
[17]. Of the few studies that combined US and lipofection,
one example highlights the challenges of this method. For
example, brain tumor cell transfection using 2MHz pulsed
US for 1min and Lipofectamine condensed with plasmids
coding for green ﬂuorescent protein (GFP) produced no
change in transfection eﬃciency compared to conventional
lipofection alone [18]. Therefore, it appears that lipofection
is not enhanced by US unless gas bubbles are introduced in
the liposome or present as a separate agent. If gas bubbles are
present, the transfection by naked DNA + US then appears
to be eﬀcient in vitro. However, there are several advantages
with respect to enhanced durability when plasmids are
complexed with cationic lipids.
3.1.2. Polymeric Nanoparticles. Polymers used for drug and
gene delivery typically include polystyrene (PS), poly(lactic
acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), and poly-
plexes of plasmids and cationic polymers. Application of US
to solid polymeric nanoparticles appears to be eﬀective in
reducing cavitation threshold in water, even in the absence
of preformed gas bubbles [19]. For example, we have shown
that PS nanoparticles can reduce the threshold of US-
induced cavitation activity in pure water from about 7.3
bar to <5 bar, depending upon the size and concentration
used [1, 20]. We observed that the threshold decreased with
increasing particle concentration and particle sizes [1, 20].
Thus, even without the use of gas bubble contrast agents,
there was suﬃcient cavitational activity to produce signiﬁ-
cant bioeﬀects. Although other investigators have used other
polymer and polyplex nanoparticles, they did not report
whether these particles lowered thresholds or enhanced US
activity. For potential translational applications, it would
be very beneﬁcial to know whether other types of solid
nanoparticles can lower the cavitation threshold in blood or
in intracellular liquids.
One important reason for selecting NP over commercially
available MBs as sonoporation enhancers is the ability of NPs4 Journal of Drug Delivery
to extravasate in capillaries and beyond, whereas MBs cannot
due to their larger dimensions. In fact, this capability of NPs
enables their eﬃcient delivery to tumor cells, where US can
then induce spatially conﬁned cavitational activity (sono-
poration) to enhance gene delivery. For example, we have
shown that approach allowed for vasculature disruption only
in US-irradiated tumors of nude mice, while no disruption
was observed in nonirradiated controls [21]. In another
study, we investigated the inﬂuence of polystyrene nanopar-
ticles (100 and 280nm in diameter and concentration up to
0.2%w/w) on cavitation threshold in water at the frequency
of 20kHz. Then, we studied eﬃcacy of cancer chemotherapy
with this technique in vivo. The experiments were performed
in athymic nude mice bearing human colon KM20 tumors,
which are highly resistant to chemotherapy. Ultrasound with
the frequency of 20kHz in combination with i.v. injected
polystyrene nanoparticles was applied to enhance delivery
of chemotherapeutic agent 5-ﬂuorouracil [1]. Our studies
demonstrated that US irradiation in combination with the
NPanddruginjectionssigniﬁcantlydecreasedtumorvolume
andresultedincompletetumorregressionatoptimalirradia-
tion conditions, while the volume of control (nonirradiated)
tumors increased despite drug injections. These data suggest
that US-induced drug delivery may improve eﬃcacy of
current cancer treatment regimens, suggesting PS + US do
not cause signiﬁcant tumor cell toxicity and can be used
safely to deliver drugs or nucleic acids. For instance, when
PS + US were used to deliver 5-FU, the antitumor eﬀect was
augmented dramatically for this drug, with a 60% growth
ratereductionandenhancednecrosisthroughoutthetumors
as observed by histology. Another in vivo study showed
that polystyrene nanoparticles decrease cavitation threshold
in water, and application of this drug delivery technique
substantially improved the eﬃcacy of cancer therapy in nude
mice with colon tumors when US was used in combination
with polymer NP injections [20].
Gene Delivery by Polymeric PLGA Nanoparticles. Several
studies have shown eﬃcient US-enhanced gene delivery
using polyplexes of DNA and cationic-derivatized natural
polymers, such as cationized dextran [22]a n dg e l a t i n[ 23].
In these experiments, 3MHz US (2 W/cm2, 10% duty cycle)
typically was applied for 1 to 2 minutes transdermally to
various tissues in vivo such as tumors or muscle. Insonation
always enhanced gene expression for a few days. The authors
speculated that cavitation-induced cell membrane damage
and permeation were responsible for the enhanced gene
expression.
Arguably, superior polymeric nanoparticle formulations
for gene delivery using US may be composed of PLGA, a
polymer approved by the FDA for its excellent proﬁle of
biodegradability, drug biocompatibility, suitable biodegra-
dation kinetics, mechanical properties, and ease of pro-
cessing (reviewed in [24]). PLGA and its derivatives have
been the center focus for developing nano/microparticles
encapsulating therapeutic drugs in a biodegradable format.
Many macromolecular drugs including proteins, peptides,
genes, vaccines, antigens, and human growth factors can be
incorporated successfully into PLGA- or PLGA/PLA-based
nano/microparticles.Andseveralmicroparticleformulations
already are available in the market (reviewed in [25]). How-
ever, intense research is ongoing to reﬁne and enhance
PLGA-based NP over other delivery systems, including
developing blends of PLGA with other polymers, for exam-
ple, chitosan, pectin, poly(propylene fumarate), poloxamers
and poloxamines, polypyrroles, gelatin, poly(vinyl alcohol)
(PVA),PVA-chitosan-PEG,andpoly(ortho-esters)(reviewed
in [25]). These novel technologies can produce PLGA- and
PLGA-based nano/microparticles for drug delivery and can
dramatically expand the new ﬁeld for eﬃcient drug/gene
delivery if the nanoparticles can be rendered echogenic or
acoustically active.
Biodegradable PLGA NPs can sustain delivery of drugs,
proteins, peptides, and plasmid DNA, owing to their ability
to protect macromolecules from degradation in endolyso-
somes (reviewed in [26]). NPs have distinct advantages for
drug delivery since they can penetrate deep into tissues
through ﬁne capillaries, across fenestrations present in the
epithelial lining and, generally, are taken up eﬃciently by
the cells, allowing eﬃcient delivery of therapeutic agents.
NPs also have the advantage of sustaining the release of
the encapsulated therapeutic agent over a period of days
to several weeks compared with natural polymers that have
a relatively short duration of drug release [27]. The safety
of PLGA-based NPs in the clinic has been well established
[28] and polyethylene-glycol- (PEG-) conjugated PLGA NPs
are currently emerging as molecules with reduced systemic
clearance compared with similar NPs lacking PEG [29].
Therefore, the ﬁeld of gene delivery will continue to reﬁne
and expand into PLGA NP for in vivo use, particularly with
US-mediated enhancements in eﬃciency.
Deﬁning Sonoporation Parameters for Successful Gene Deliv-
ery Using NP. Eﬃcacy and safety of cancer chemo- and
biotherapy are limited by poor penetration of anticancer
drugs from blood into tumor cells. Tumor blood vessel wall,
slow diﬀusion in the interstitium, and cancer cell membrane
create signiﬁcant physiological barriers for macromolecular
agents. We have used nano- and microparticles in tumors
followed by ultrasound-induced cavitation for safe and eﬃ-
cientdrugandgenedelivery.Inseveralstudies,sonoporation
has eﬀectively enhanced anticancer drug or gene delivery in
tumorcellsandtissues.Inourexperience,sonoporationdoes
notappeartonegativelyimpactcellularviabilityofinsonated
tumor cells or normal surrounding tissues after treatment
with either chemotherapeutic drugs [2] or plasmid DNA in
vitro [30]o rin vivo [4] when MBs are utilized as the gene
carrier (Optison or SonoVue). SonoVue is an ultrasound
contrast agent made of MB stabilized by phospholipids and
containing sulphur hexaﬂuoride (SF6), an innocuous gas
[31] and manufactured by Bracco Diagnostics Inc, USA.
Optison is an ultrasound contrast agent, consisting of gas-
ﬁlled MBs surrounded by a solid shell of heat-denatured
human albumin [32] resulting in a size range of 2.0 to
4.5μm and manufactured by GE Healthcare, USA. For
example, we have shown minor damage to MCF-7 breast
cancer cells following exposure to low-intensity US in the
presence of either Optison MB or a chemotherapeutic drug,Journal of Drug Delivery 5
5-ﬂuorouracil (5-FU) as assessed by low lactate dehy-
drogenase (LDH) release (a measure of cytotoxicity) and
MTT cell viability assays. However, depending on the US
parameters chosen, temperature changes can be observed in
vitro. For example, increases in US duty cycle enhanced cell
death associated with either Optison or 5-FU, using 3MHz
and 2W/cm2 for 1min, while temperature changes were
negligible at low US duty cycles (5%). When a duty cycle of
20% was used, heating occurred from 18◦Ct o3 6 ◦C, while,
at a duty cycle of 50%, heating rose up to 40◦C. Optison at
10% appeared to protect cells from the US heating bioeﬀects.
Cell viability was decreased by Optison dramatically when a
50% duty cycle was used and augmented by 5-FU delivery.
Therefore, careful selection of US parameters is required to
avoidanyheating andcelltoxicity. Interestingly, immediately
after treatment, cell death was most dependent on Optison;
however,24haftertreatment,celldeathwasmoredependent
on 5-FU, and the best minimal eﬀective dose for cell
killing was 10μg/mL. Furthermore, treatment with 5-FU
and US increased the levels of Bax and p27kip1 proapoptotic
proteins, but the addition of Optison appeared to suppress
apoptotic protein expression. This study clearly illustrates
the need for experimental design aimed at dissociating
speciﬁc from nonspeciﬁc toxicity eﬀects of a gene or drug
delivered by sonoporation in order to better reﬁne the
conditions for delivery in vivo. Another detailed study that
illustrated the importance of examining the best parameters
for delivering macromolecules used a macromolecule that
modeled the Mw of drugs or plasmid DNA and delivery
with Optison [1, 30], whereby transfection was obtained
up to ∼37% with minimal cell death, identifying optimal
parameters of US exposure able to produce eﬃcient delivery
of macromolecules.
Like MBs, in our experience, echogenic nanoparticles
made from polystyrene (PS) or PLGA also do not appear to
produce any toxic eﬀects in the presence of US. For example,
inaninvivoDU145prostatecancermodel,noalterationsare
seen histologically to indicate cell death in tissues for PLGA
NP plus US, even in the presence of pDNA:PEI complexes
[3]. The next section will cover in detail strategies for US-
mediated DNA delivery with PLGA and PEI:pDNA NP in
vivo.
3.1.3. Ultrasound Enhances Gene Delivery by PLGA When
pDNA Is Complexed with Polycationic Polymers. Over the
years, a signiﬁcant number of cationic polymers have been
explored as carriers for gene delivery (reviewed in [33])
since they condense DNA into small particles and facilitate
uptake by endocytosis. One of these cationic polymers is
poly(ethyleneimine)orPEI(reviewedin[34]).Thepotential
of PEI was ﬁrst described for gene delivery applications in
1995 [35]. Several molecular weights of PEI have been inves-
tigated with the most suitable forms ranging in 5–25kDa
[36, 37]. Higher-molecular-weight PEI increases cytotoxicity
due to polymer aggregation at the cell surface [38]. Low-
molecular-weight PEI is less toxic yet is usually less eﬀective
for gene delivery, since the lower amount of positive charges
permoleculemakesitdiﬃcultforsmallPEIstoappropriately
condense negatively charged DNA molecules. Gene delivery
research has used either hyperbranched or linear PEI, and
branched PEI has shown stronger complexation with DNA
since it typically forms smaller complexes DNA:linear PEI
[39]. The condensation behavior of branched PEI:DNA is
less dependent on buﬀering than high-molecular-weight
PEI,yetthetransfectioneﬃciencyoflinearPEI(22kD):DNA
complexes is typically higher than that of branched PEI
(25kD) when prepared in a salt-containing buﬀer [39]. in
vivo, linear PEI:DNA complexes prepared in high salt con-
ditions are 100-fold less active than complexes prepared in
low salt conditions, suggesting eﬃcient transgene expression
depends greatly on the size of DNA complexes.
Recently, we have shown that linear PEI (in vivo JetPEI)
can enhance echogenic PLGA NP plasmid DNA (pDNA)
delivery in vivo with US. Several ways exist to produce
PLGA:PEI:pDNA particles from the original PLGA structure
and branched or linear PEI molecules and these are depicted.
The order in which PLGA particles are formulated with
polycation PEI appears to aﬀect gene expression magnitude.
For example, Zhang et al. (Figure 3(a))h a v ec o m p a r e d
three formulation methods for preparing microparticles
containing PLGA PEI and pDNA and evaluated the meth-
ods for buﬀering capacity, cellular uptake, transfection
eﬃciency, and toxicity. In the ﬁrst method, PLGA PEI
pDNA microparticles are prepared by entrapping pDNA
in blended PLGA/PEI using the double emulsion water-in-
oil-in-water solvent evaporation technique (PA) [40]. In a
second approach, PEI-pDNA polyplexes are prepared and
then entrapped in PLGA microparticles using a double
emulsion solvent evaporation method (PB). Microparticles
prepared using formulation methods PA and PB are then
compared against PLGA microparticles with PEI conjugated
to the surface using carbodiimide chemistry (PC); 0.5% PVA
is identiﬁed as the optimum concentration of surfactant for
generating the strongest transfection eﬃciencies. N:P ratios
of 5 and 10 are selected for preparation of each group. Gel
electrophoresis demonstrated that all PLGA formulations
had strong pDNA binding capacity with signiﬁcantly lower
in vitro cytotoxicity for PLGA PEI microparticles than for
PEI alone. PLGA PEI pDNA microparticles mediate higher
cellular uptake eﬃciency and consequently higher transgene
expression than unmodiﬁed PLGA microparticles in COS7
and HEK293 cells.
Preparing PEI-pDNA polyplexes prior to entrapment in
PLGA microparticles (PB) results in a higher pDNA load-
ing capacity than pDNA loaded onto unmodiﬁed PLGA
microparticles. PLGA PEI pDNA microparticles prepared
in this manner and with a N:P ratio of 5 provide the
strongest transfection eﬃciency, which is ∼500-fold and
∼1800-fold higher than that obtained with unmodiﬁed
PLGA pDNA microparticles in HEK293 cells and in COS-7
cells, respectively, (Figure 3(a))[ 40]. One downside of this
formulation strategy is that the particles generated are in
the micron range, limiting systemic in vivo use. This study,
however, guided our rationale for developing improved
PLGA:PEI:pDNA particles, whereby strategy reﬁnement was
achieved by producing instead echogenic nanoparticles of
PLGA. For our studies, we selected linear PEI (LPEI)
(Figure 3(b))[ 3] since it is reportedly less toxic to cells than6 Journal of Drug Delivery
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Figure 3: Diﬀerent strategies to complex DNA with PLGA-based nanoparticles. (a) Structure of polylactic-co-glycolic acid (PLGA) and
linear polyethylenimine (PEI). A branched PEI can also be utilized to form complexes. (b) Schematic of the preparation methods of PLGA
formulations using methods that result in plasmid DNA incorporation on the inside or the surface of PLGA particles as reported in [3, 40].
its branched counterparts, perhaps due to mediating a lower
condensation of LPEI:DNA complexes and a more eﬃcient
intracellular dissociation following uptake. LPEI:DNA com-
plexes have been shown to enter the nucleus more readily
than branched PEI:DNA [39].
The PLGA:PEI:pDNA complexes shown in Figure 3(b)-
(4) are eﬀective in delivering genes to the lung (Fig-
ure 4(a)) and prostate tumors when ultrasound is applied
(Figure 4(b)). Pulmonary gene delivery can be an excellent
route for gene therapy of lung-related genetic diseases and
may induce immunity towards pathogens entering the body
via the airways. For example, PLGA NPs prepared bearing
polyethyleneimine (PEI) on their surface were characterized
for their potential to transfect the pulmonary epithelium
[41]. These particles were synthesized at diﬀerent PLGA-
PEI ratios and loaded with DNA in several PEI-DNA ratios,
exhibiting narrow size distributions, with mean particle sizes
ranging from 207 to 231nm. Zeta potential was strongly
positive (>30mV) and loading eﬃciency high (>99%).
Internalization of the pDNA-loaded PLGA-PEI NP was
examined in the human airway submucosal epithelial cell
line, Calu-3, and gene expression was detected in the endo-
lysosomal compartment as soon as 6h following application
of particles (Figure 4(a)). NP cytotoxicity was dependent on
the PEI-DNA ratio and the best cell viability was achieved
by PEI-DNA ratios of 1:1 and 0.5:1. Although this example
did not use US to mediate gene delivery, it illustrated the
potential of PLGA-PEI NP for achieving lung epithelium
transfection as well as the importance of carefully titrating
the ratio of PEI to pDNA in order to not exacerbate this
cationic polymer toxicity eﬀects.
In our in vivo studies with similar PLGA:PEI:pDNA
NP, we have shown that polyplexes of β-gal reporter gene
plasmid DNA and linear polyethyleneimine derivative (in
vivo JetPEI) can be formed and complexed with ∼200nm
echogenic PLGA NP [3]. PLGA:PEI:pDNA complexes were
administered into DU145 prostate tumor-bearing nude mice
and, immediately after, a low-intensity US was applied to the
tumor site. Pulsed insonation for 5 minutes at 1MHz and
−7 bars produced a signiﬁcantly greater expression of theJournal of Drug Delivery 7
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Figure 4: PLGA nanoparticles deliver plasmid DNA eﬃciently in vitro and in vivo.( a )In vitro delivery: cellular internalization in calu-3
cells 6 h after application of PLGA-PEI nanoparticles loaded with rhodamine-labeled GFP encoding plasmid DNA. (1) Immunoﬂuorescence
of anti-lysosomal-associated-membrane-protein-1 (LAMP-1) (red), (2) intracellular distribution of rhodamine-labeled DNA (green), and
(3) superimposition of the confocal micrographs indicating colocalization of the DNA in the lysosomal compartments (orange-yellow).
Reproduced with permission from [41]. (b) In vivo delivery: a special formulation, PLGA:PEI:DNA is excellent for I.V. gene delivery in vivo.
(a) Bgal expression in control (left) and ultrasonicated (right) tumors with PLGA/PEI/DNA complex nanoparticles injected intravenously.
Light scattering microscopy images taken at 20x; bar represents 100μm. ∼10% of tumor cells are transfected in ultrasonicated tumors
compared to controls (∗P < 0.01). Reproduced from [3] with permission from Elsevier. (c) Percentage of B-galactosidase-positive (Bgal+)
cells in DU145 tumors in the absence of ultrasound (−US) and presence of US (+US). ∗P < 0.05. (d) Western blot showing the levels of B-gal
protein are higher in tumors that received US (+US) compared to those without US treatment (−US). Levels of B-gal are shown relative to
those of a control housekeeping protein, beta-actin.
reporter gene in the tumor (∼10% cells are positive for the
reporter gene LacZ) compared to the noninsonated bilateral
control tumor (∼1% cells positive for LacZ gene) (Figure 4).
Therefore, US augmented gene delivery in vivo. One impor-
tant component of these studies was the echogenic property
of the PLGA nanoparticles. These particles were prepared in
a manner that resulted in “air-ﬁlled” particles that were able
to oscillate in the acoustic ﬁeld, which likely stimulated their
or DNA uptake by endocytosis. The particles zeta potential
was 13.4 ± 2.6mV, and echogenicity properties were tested
using ultrasound imaging, which revealed a similar acoustic
activity as standard Deﬁnity microbubble particles. Deﬁnity
particles are lipid-encapsulated microbubbles containing
perﬂuoropropane gas ranging in size from 1.1 to 3.3μm
[42] and manufactured by Bristol-Myers Squibb Medical
Imaging, US. The overexpression of the β-gal reporter gene
delivered was examined by X-gal staining and Western
blot, and at least an 8-fold increase was observed in cell
transfection eﬃciency in irradiated tumors compared to
nonirradiated control. Negligible cell death was produced
by ultrasonication and we determined the pDNA condensed
by PEI was protected from degradation even under US8 Journal of Drug Delivery
conditions. These results indicated that this formulation is
promising for in vivo gene delivery of plasmid DNA using
sonoporation. PLGA and PEI each are formulation choices
that have certain advantageous chemical and structural
characteristics that can enhance pDNA delivery in tumor
cells. The advantage of PLGA, as discussed earlier, is the
biodegradability proﬁle and echogenicity of the prepared
NP. The advantage of the in vivo jetPEI, as shown by our
data, was its ability to protect pDNA from any potential
US-induced damage. Also, PEI could further enhance NP
translationpotentialasthispolymeralreadyhasbeenutilized
in clinical trials for bladder cancer [43]. Moreover, an
important rationale for using PEI to condense pDNA and
complex it to the surface of echogenic PLGA NP is to
enable delivery of a large amount of pDNA (≥50μg) [3],
which is usually necessary to achieve eﬃcacy in in vivo
gene therapy settings [4], while still preserving the nanoscale
dimensions of the chimeric NP (∼200nm). In some cases,
pDNA can be loaded inside the PLGA NP, but usually this
results in minimal encapsulation (5%) for this NP type,
requiring a microparticle production. For example, IL-10
is an anti-inﬂammatory molecule that has achieved interest
as a therapeutic for neuropathic pain. In one recent study,
encapsulation of plasmid was low (only ∼8μg pIL-10) when
PLGA microparticles of ∼4.6μm were utilized to deliver IL-
10 [44]. And although this PLGA:pIL-10 therapy was able
to relieve neuropathic pain for greater than 74 days in an
animal model following direct intrathecal administration, a
micron-sized particle such as this may be less desirable for
tumortherapyandtargeting,forexample,aspenetrationand
retention into tumor vasculature is desired with or without
using sonoporation for gene delivery. However, reﬁnements
are possible that will allow incorporation of other choices of
cationic polymers for DNA condensation and loading onto
echogenic PLGA NP for further reductions in any potential
PEI in vivo toxicity [38, 45], and potential approaches will be
discussed as follows.
Another polycation that would potentially be useful
for condensing pDNA while enhancing US-mediated gene
delivery is poly(L-lysine) or PLL, which has been used widely
in gene therapy studies. One interesting recent study has
shown that improvements can be made to PLL to reduce
cytotoxicity and enhance transfection eﬃciency. This more
eﬃcient polymer is composed of short oligolysine grafts
strung from a hydrophobic polymer backbone [46]a n d
gives transfection eﬃciency greatly superior to PLL. The
oligolysinegraftlengthwasalteredtoimproveDNA-polymer
interactions and overall transfection eﬃciency. Additionally,
whenPKKKRKVheptapeptides (theSimianvirusSV40large
T-antigen nuclear localization sequence) were added onto
theoligolysinepolymerbackbone,transfectioneﬃciencywas
furtherenhancedandreportergeneexpressionlevelsreached
levels higher than, or comparable to, JetPEI, FuGENE 6, and
Lipofectamine 2000, the latter being notorious for cytotoxic-
ity accompanying high transfection eﬃciency. Using heparin
decomplexation assays, the mechanism for the enhanced
gene delivery was determined to involve the relative strength
of the polymer-DNA complex, contributing to the therapeu-
tic promise of these novel oligolysine reagents since they are
able to better release DNA during the transfection process
following nuclear uptake.
Another potential DNA condensation agent for high-
level gene delivery would involve the use of dendrimers of
poly(amidoamine) or PAMAM. These have several advan-
tages over PEI in vitro and in vivo, including a lower
toxicity proﬁle and reduced nonspeciﬁc lung transfection.
An interesting recent study has shown that pDNA con-
densed with PAMAM starburst dendrimers (generation 4
and 5) can eﬃciently transfect tumor cells in vitro and
in vivo [47]. Following intravenous injection of polyplexes
into immunecompetent mice bearing subcutaneous, well-
vascularized murine neuroblastoma (Neuro2A), luciferase
reporter gene expression was detected predominantly in
the tumor, while negligible transgene expression levels were
detected in other organs as determined by bioluminescent
in vivo imaging (BLI) (Figure 5(a)). Compared to linear PEI
(LPEI), Luc expression was relatively higher and lung signals
were greatly reduced for PAMAM-G5:pLuc, indicating this
is a promising polyplex for in vivo gene delivery to tumors.
Additionally,repeatedapplications ofthis polyplex typewere
well tolerated and resulted in prolonged average transgene
expression in tumors as determined by BLI (Figure 5(b)).
Fluorescence in vivo imaging using these polyplexes labeled
with near-infrared emitting semiconductor quantum dots
revealed that, although lung accumulation was similar for
both PAMAM and LPEI polyplexes, only LPEI polyplexes
induced high luciferase expression in lung. The mechanism
proposedmayinvolveaggregationofLPEI:pDNAwithblood
components that can induce backpressure in the blood ﬂow,
pushing plasmid through the lung endothelium into the
vicinityofalveolarcells.AlveolartypeIIpneumocytes,beside
endothelial cells, comprise the major fraction of transfected
cells following of LPEI:pDNA i.v. injection. Therefore the
authors concluded that although PAMAM polyplexes were
trapped within the lung due to charge interactions, the
occlusion of capillaries might not be eﬀective enough to
induce eﬀects similar to LPEI in lung, and transfection
signals are not detectable. At any rate, the PAMAM-G5
dendrimer could be a potential candidate for loading pDNA
onto echogenic PLGA NP since, as PEI, it promises to have
highly desirable characteristics of enhanced gene delivery
that is restricted to tumors and a reduced oﬀ-target (lung)
reporter gene expression in vivo. Finally, another promising
new cationic polymer that could be a great candidate
for complexing with PLGA is one containing a branched
oligoethyleneimine (OEI, 800Da) core, diacrylate esters
as linkers, and oligoamines as surface modiﬁcations [48].
Although complex in structure, these are also promising
since they exhibit low cytotoxicity in vivo and were shown
to transfect tumor tissue at levels comparable to those
with PEI but were better tolerated with no change in liver
histology or liver enzymes, while LPEI and BPEI resulted in
an increase in liver enzyme levels, suggesting early necrotic
stages in liver 24h after treatment. OEI also exhibited a
more tumor-speciﬁc gene expression proﬁle than when PEI
was used, with lower lung transgene expression. Finally,
dendrimers also can be used to target nucleic acid delivery
to particular cells or tissues using cell-penetrating peptides.Journal of Drug Delivery 9
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Figure 5: PAMAM-dendrimer-based complexes may be an alternative to PEI for pDNA delivery in vivo using NP. (a) PLGA:PAMAM-G5
gives higher tumor expression of reporter pDNA and lower nonspeciﬁc lung transfection for a more favorable biocompatible proﬁle in
vivo. In this example, A/J mice with subcutaneous Neuro2A tumors received a single intravenous injection of LPEI polyplexes N/P 6 (1)
or PAMAM-EDA G5 polyplexes charge ratio 2.9/1 (2) containing plasmid pCpG-hCMV-Luc (2.5mg/kg based on pDNA) and BLI was
carried out 24 h later. Reprinted with permission from [47]. (b) Prolonged reporter gene expression in Neuro2a following intravenous
administration of pCpG-hCMV-Luc/PAMAM-EDA G5 polyplexes (±2.9). Reprinted with permission from [47]. (c) PLGA:PAMAM G5-
PEG nanoparticles deliver plasmid DNA more eﬀectively (muscle) than G5. Reprinted with permission from [54].
Forexample,PAMAM-G5dendrimersdisplayingcyclicRGD
targeting peptides (PAMAM-RGD) improved transport [49]
and also could deliver siRNA in polyplex complexes of
∼200nm, mediating more eﬃcient nucleic acid delivery
through multicellular 3D U87 glioma spheroids than that of
native PAMAM dendrimers, presumably by interfering with
integrin-ECMcontactspresentinathree-dimensionaltumor
model [50].
Although highly eﬃcient nonviral gene carriers, one
common drawback of LPEI, PLL, and PAMAM dendrimer
cationic polymers is that these may present a high toxicity in
vivo, even if a relatively low cytotoxicity is initially observed
in vitro. Therefore, some solutions have included surface
modiﬁcation to signiﬁcantly help reduce their toxicity [51–
53]. For example, to help expand the in vivo applications
of PAMAM, one study attempted to improve characteristics10 Journal of Drug Delivery
of this polymer as a gene delivery carrier by incorporation
of polyethylene glycol (PEG, molecular weight 5,000). PEG
is known to convey water solubility and biocompatibility
to conjugated copolymers and usually does not adversely
aﬀect self-assembly of copolymer with pDNA, still allow-
ing nanosized complex formation with a narrow particle
size distribution. When PEG was conjugated to G5 and
G6 PAMAM dendrimers (PEG-PAMAM) at three diﬀerent
molar ratios of 4%, 8%, and 15% (PEG to surface amine
per PAMAM dendrimer molecule) [54], in vitro and in vivo
cytotoxicities were reduced signiﬁcantly. Also, hemolysis was
reduced, especially at higher PEG molar ratios. Among all
of the PEG-PAMAM dendrimers, 8% PEG-conjugated G5
and G6 dendrimers (G5-8% PEG, G6-8% PEG) were the
most eﬃcient in delivering genes to muscle following direct
administration to neonatal mouse quadriceps (Figure 5(c)).
Consistent with the in vivo results, these two 8% PEG-
conjugated PAMAM dendrimers could also mediate the
highest in vitro transfection in 293A cells. Therefore, G5-
8% PEG and G6-8% PEG possess a great potential for
gene delivery and could conceivably be adapted to con-
dense nucleic acids and be loaded atop echogenic PLGA
NP for US-mediated enhancements in intramuscular gene
delivery.
Other preparations successful in intramuscular gene
delivery have been described, of interest since they enhance
US-mediated gene delivery. These include eﬃcient gene
transfer in muscle to deliver basic ﬁbroblast growth factor
(bFGF) angiogenic gene therapy in limb ischemia. Bub-
ble liposomes (DSPE-PEG2000-OMe with perﬂuoropropane)
were used to transfect muscle in the presence of US [55]. In
this example, bFGF was delivered and capillary vessels were
enhanced and blood ﬂow improved in the bFGF + MB + US-
treated groups compared to other treatment groups (non-
treated, bFGF alone, or bFGF + US). Skeletal muscle is a
target of interest for gene delivery since it can mediate gene
therapyofbothmuscle(e.g.,DuchenneMusculardystrophy)
andnonmuscledisorders(e.g.,cancer,ischemia,orarthritis).
Its usefulness is due mainly to the long-term gene expression
proﬁle following gene transfer, which makes it an excellent
target tissue for the high-level production of therapeutic
proteins such as cytoskeletal proteins, trophic factors, hor-
mones, or antitumor cytokines. Reﬁning the conditions
for sonoporation as well as the optimal formulation for
achieving high-level transgene expression in skeletal muscle
will continue to be an important focus of gene therapy
delivery eﬀorts for treating tumors, and in particular the
delivery of antitumor cytokines.
3.1.4. MB Can Enhance NP Gene Delivery by Sonoporation
in Muscle Tissue. An interesting concept to aid NP gene
delivery by sonoporation has employed combination with
microbubbles in vivo. In one example, the hypothesis was
tested that combination of a low concentration of MB
could help reduce any US bioeﬀects and allow similar
levels of transfection to occur when using PLGA NP at a
lower US intensity and with a shorter duration in time.
One interesting study examined the potential of improving
siRNA delivery of retinal cells (RPE-J) in the presence of
PLGA NP and a small amount of SonoVue MB [56]. Low-
intensity US or 15–20% SonoVue MB also increased the
siRNAdeliveryeﬃciencywhenalowerconcentrationofPEG
and Poly-lysine-conjugated PLGA particles were used. The
combination of US with MB was used to select the optimal
enhancement of NP delivery but did not furhter increase
the cellular uptake of NP, but it achieved signiﬁcantly higher
PDGF-BB gene silencing compared to NP alone.
Another example of combining NP with MB to enhance
gene delivery is shown in Figure 6. This study showed
that gene delivery of recombinant growth factors to stim-
ulate arteriogenesis is possible through a combination
of NP, an albumin-based MB contrast-agent, and US in
vivo (Figure 6(a))[ 57]. After verifying that ultrasonic MB
destruction eﬀectively deposited intravascular polystyrene
nanoparticles into mouse adductor skeletal muscle, FGF-
2-bearing biodegradable PLGA NPs (FGF-2-NP) were gen-
erated and coadministered intraarterially with MB, and
delivery was spatially targeted to ischemic mouse hind limbs
using1MHzUS.ThedeliveryofFGF2-NPstimulatedappre-
ciable arteriogenic remodeling in ischemic mouse hind-limb
adductor muscles. This response included an increase in the
total number of large and moderate diameter arterioles (i.e.,
>15μm in diameter), as well as a marked luminal expansion
of both collateral and transverse arterioles (Figure 6(b))
t w ow e e k sa f t e rt r e a t m e n t .T h i ss y s t e me ﬃciently delivered
PLGA FGF2-NP to mouse muscle in a model of hind-limb
arterial insuﬃciency. This method has several features that
may enhance its potential for successful clinical translation,
including minimally invasive targeting, sustained growth-
factor delivery, and retention of growth factor bioactivity.
Ultimately, these results indicate that ultrasonic MB destruc-
tionhaspotentialasaplatformfortherapeuticdeliveryofNP
invivoforvascularremodeling,anddependingonantitumor
therapeutics chosen, this may have important implications
also for tumor therapy using cytokine gene delivery, for
example.
3.1.5. Future Formulations: Promise for Echogenic PEGylated
or Dendrimer PLGA Formulations. As we have shown, PLGA
NPcanbeechogenicandserveasacontrastagentinaddition
to as a gene delivery vehicle. For example, in vivo ultrasound
imaging can be accomplished with a high-resolution small
animalimagingsystemandisillustratedinFigure 7.Weshow
an example of US imaging for examining the kinetics of
PLGA NP in vivo (prostate tumors) by using novel, high-
resolution ultrasound imaging system Vevo 770 developed
by VisualSonics (Toronto, Canada). The system has the
ability to visualize and quantify tumors, hemodynamics,
and therapeutic interventions with resolution down to 30
microns noninvasively and in real time. Figure 7(a) shows an
image of a DU145 prostate tumor in a nude mouse obtained
with the system following intravenous administration of
PLGA NP (same NP as described in Figure 4(b)). The
system was capable of detecting the distribution of an
unlabeled ultrasound contrast agent (UCA, VisualSonics)
and allowed its visualization in the tumor (the areas with
high concentration are represented in green). A specially
developed computer code allowed to quantify kinetics ofJournal of Drug Delivery 11
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Figure 6: Nanoparticle uptake can be enhanced by ultrasonication in the presence of microbubbles in skeletal muscle in vivo. (a) Gracilis
skeletal muscle cross-sections illustrating ﬂuorescent polystyrene nanoparticle (NP) delivery for each treatment. (A)–(I) Muscle treated with
ultrasound (US) + microbubbles (MB) + nanoparticles (NP) combinations. For the conditions of US + MB + NP, NPs (red) accumulate in
vessel walls and muscle interstitium (BS-1 lectin staining, green). For muscle treated with US + NP, NPs colocalized with endothelium but
minimal interstitial deposition was observed. Muscle treated with MB + NP was almost void of NP. (J) Bar graph representing the fraction
of interstitial area (regions outside of muscle ﬁbers and vascular structures) or endothelial cell area (cells comprising the walls of blood
vessels) occupied by NP. Values are means with standard deviations. ∗indicates signiﬁcantly diﬀerent (P < 0.05) than interstitial area of all
other groups. +indicates signiﬁcantly diﬀerent (P < 0.05) than endothelial cell area of all other groups. (b) The delivery of FGF-2 bearing
nanoparticles by ultrasonic microbubble destruction elicits arteriogenic remodeling in gracilis adductor muscle. (A)–(D) Representative
whole-mountimagesofﬂuorescentlylabeledSMα-actin+vesselsingracilisadductormuscles7and14daysafterFGF-2(A)and(B)andBSA
(C)and (D) treatment. Note thesigniﬁcant increase in arteriolar caliber and densityin FGF-2-treated muscles. (E) Bar graph of arterioleline
intersectionsatbothtimepointsforFGF-2,BSA,andshamsurgerytreatment.Valuesaremeanswithstandarderrors. ∗indicatessigniﬁcantly
diﬀerent (P < 0.05) than BSA and sham surgery at day 14. Reprinted from [57] with permission from Wiley.
this UCA in the tumor (Figure 7(a), right panel). There
was a sharp increase of the concentration in the whole
tumor within ﬁrst 2 to 3 seconds after the injection that
was followed by a wash-out process (decrease of the contrast
intensity). The necrotic areas at the center of the tumor
had similar kinetics but less concentration of the UCA
due to lower vascularization (Figure 7(b),l e f tp a n e l ) .I n
contrast, injection of the PLGA nanoparticles into the same
mouse (after clearance from the UCA) demonstrated almost
constant concentration of the PLGA nanoparticles 15 sec-
onds after the injection (Figure 7(b), right part). This eﬀect
resulted from competition of two processes: (1) the decrease
of nanoparticles concentration in blood and (2) the increase
of their concentration in the tumor blood vessels due to12 Journal of Drug Delivery
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Figure 7: . Echogenic PLGA nanoparticles can be utilized also as ultrasound contrast agents in vivo. (a) (1) A tumor image obtained with
the high-resolution ultrasound system VEVO770 (VisualSonics). (2) Kinetics of the contrast agent in the whole tumor shown in (1). (b)
(3) Kinetics of the contrast agent in the central area of the tumor shown in (1). (4) Kinetics of the PLGA nanoparticles in the whole tumor
s h o w ni n( 1 ) .
the EPR eﬀect. Moreover, the contrast intensity produced by
the PLGA nanoparticles (∼175) was much higher compared
to that of the UCA (∼100). These data indicate that high-
resolutionultrasoundsmallanimalsimagingsystemsareable
to detect the PLGA nanoparticles in tumors in vivo and that
these nanoparticles are highly echogenic.
Further modiﬁcations can be made to echogenic PLGA
NP to enhance their potential for longer circulation half-
life and for enabling tumor-speciﬁc targeting. For example,
surface modiﬁcations can be made to polymeric nanopar-
ticles to add PEGylated phospholipids in order to escape
recognition and clearance by the mononuclear phagocyte
system and achieve passive tumor targeting. Nanopar-
ticles consisting of a shell of PLGA encapsulating a
liquid core of perﬂuorooctyl bromide (PFOB) can be
decorated with poly(ethylene glycol-2000)-grafted dis-
tearoylphosphatidylethanolamine (DSPE-PEG) and result-
ing particles still are echogenic and can allow visualiza-
tion of MIA-PaCa-2 pancreatic tumors in vivo, following
intratumoral or intravenous injection (Figure 8(a)). In this
example, the tumor was visualized only following intra-
tumoral UCA injection. Despite the absence of echogenicJournal of Drug Delivery 13
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Figure 8: PEG-PLGA particles as ultrasound contrast agents in vivo. (a) Ultrasound images of mouse pancreatic tumors obtained in a
nonlinear imaging mode before injection (1)–(3) and after intratumoral injection of plain nanocapsules (2) or PEGylated nanocapsules (4).
The tumor is indicated as the region of interest (ROI) represented by a circle. (b) Confocal microscopy images of tumor slices from a control
mouse (control) and mice after 24h of an intravenous injection of non-PEGylated nanocapsules (NC) and PEGylated nanocapsules (NCL-
PEG). DIC corresponds to diﬀerential interference Nomarski contrast. Red ﬂuorescence corresponds to PLGA dyed with Nil Red. Reprinted
from [58] with permission from Elsevier.
signal in the tumor after intravenous injection of NP,
histological analysis revealed their accumulation within the
tumor [58], and this accumulation can be explained by their
increased circulation time due to their PEGylated surface
(Figure 8(b)). PEG coating protects NC-PEG against plasma
protein adsorption and therefore against recognition by
phagocytic cells. The increased circulation time favors their
passivetargetingintumortissuebytheenhancedpermeation
and retention eﬀect [59]. A quantitative biodistribution
of NC-PEG likely would have been helpful to assessing
their actual concentration in tumors and determining the
concentration threshold necessary for ultrasonography with
these new UCAs.
4. Novel Directions
4.1. PLGA as an Ultrasound Contrast Agent. Other UCAs
recentlydevelopedbyNestoretal.includeair-ﬁllednanocap-
s u l e sm a d eo fP L G A .T h e s eh a v eac r i t i c a la d v a n t a g e
over current commercial UCAs, which are not capable of14 Journal of Drug Delivery
penetrating the irregular tumor vasculature due to their
larger dimensions. These new nanoscale UCAs based on
PLGA can therefore be used to enhance tumor detection
since they display enhanced stability compared to commer-
cially available UCAs when in the presence of US. Air-ﬁlled
nanocapsules with a mean diameter of ∼370nm have been
shown to maintain a spherical shape and thickness <50nm
and remain echogenic [60], providing an enhancement of up
to 15dB at a concentration of 0.045mg/mL at a frequency of
10MHz. Loss of signal for air-ﬁlled nanocapsules was 2dB
after 30min, suggesting high stability. This UCA therefore
has the potential to be applied to ultrasound imaging. Other
NPsthatarein development asUCAs include polymer-based
multifunctional nanoparticles that exhibit a near-infrared
absorptionandcanbeusedasanovelphotoacousticcontrast
system [61, 62]. Photoacoustics is a new imaging modality
in which laser light is shined into tissue and adsorbed by
inherent or synthetic molecules or particles and generates
ultrasound. Submicron-sized NPs with a high encapsulation
eﬃciency have been created by the incorporation of near-
infrared (NIR) dyes in PLGA via a spray-drying process.
Subsequent centrifugation yielded two size fractions ranging
from ∼445–550nm to ∼253–305nm in diameter [61, 62].
These NIR PLGA NP exhibited photoacoustic properties
using an Nd:YAG laser-based system but did not show
any detrimental eﬀects on cell viability or mitochondrial
activity. Photoacoustics properties persisted in cell culture
for up to 2 days, suggesting the excellent photoacoustic
properties plus the low cytotoxicity proﬁle renders these dye-
loaded PLGA particles promising candidates for a resorbable
photoacoustic contrast system in vivo.
4.2. The Future for Biodegradable PLGA for Gene Delivery
4.2.1. Developing Better PLGA Nanoparticles. One improve-
ment that might impact PLGA NP eﬀectiveness as a gene
delivery agent in vivo is to improve the acidic microclimate
developed during polymer degradation which can poten-
tially damage the nucleic acid that may be encapsulated or
complexed to the NP. Buﬀering agents have been used that
incorporate antacid (0, 3% MgOH2)[ 63], whereby PLGA
microspheres maintained a more homogeneous surface,
resulting in a signiﬁcant reduction of the commonly seen
“burst eﬀect.” For example, PLGA microspheres of ∼47
micron have been shown to completely release pDNA over
the course of two months, addressing some of the major
problems associated with DNA encapsulation and release.
We envision that these same buﬀering principles might be
applicable to smaller PLGA particles to help reduce any
pDNA degradation that might occur secondary to polymer
degradation prior to or following US-mediated gene delivery
in vivo.
4.2.2. Current New Technology: Nonechogenic PLGA NP Have
Been Used with Success for Targeted Drug Delivery. Several
studies have reported the use of PLGA NP or MP for
targeting drug delivery to tumor cells. These PLGA NPs are
still under development and are not echogenic. Thus, these
new approaches will be useful when adapted for the ﬁeld
of ultrasound-mediated gene delivery. We envision that the
same targeting moieties can be conjugated or complexed
onto PLGA particles with acoustic activity for future appli-
cations to gene delivery by sonoporation. We describe here
examples of targeting using PLGA NP, including the studies
described in Figure 8.I nFigure 9(a),P L G A - b a s e dM P sw e r e
produced that were able to target prostate tumor cells
expressing the prostate-speciﬁc membrane antigen or PSMA
[64]. A set of air-ﬁlled MBs of various biocompatible poly-
mer compositions were prepared and characterized in terms
of morphology and echogenic properties after exposure to
US. MBs derived from PLG-poly(ethylene glycol) (PEG)
copolymer resulted in being the most eﬀective in terms of
reﬂectivity. PLGA-PEG was therefore preconjugated before
MB preparation with an urea-based PSMA inhibitor [65].
Using this copolymer as a starting material, the MBs were
examined in vitro for their targeting eﬃcacy toward PSMA-
positive cells. Fluorescence microscopy showed a speciﬁc
and eﬃcient adhesion of targeted MBs to LNCaP cells. This
model for targeting PSMA might be further optimized for
smaller particle use (echogenic nanoparticles) and used for
prostate cancer diagnosis and drug or gene delivery.
Additional targeting moieties for PLGA NP have utilized
aptamers, which are single-stranded RNA or DNA oligonu-
cleotides ∼15–60bpinlengththatcanbindwithhighaﬃnity
to speciﬁc molecular targets. Most aptamers to proteins bind
with a Kd of ∼1pM to 1nM, which is an aﬃnity level similar
to that of monoclonal antibodies. Moreover, aptamers are
able to bind to nucleic acid, proteins, and small organic
compoundsandenabletargetingtospeciﬁccells,inamanner
similar to the concept of high-aﬃnity antibodies. For exam-
ple,atargetingnanoparticlewasdevelopedthathadamucin-
1- (MUC-1-) speciﬁc Aptamer (Apt-NP) conjugated to the
surface (Figure 9(b)). MUC1 protein is an attractive target
for anticancer drug delivery owing to its overexpression in
most adenocarcinomas. In this study, a reported MUC1
protein aptamer was exploited to target Paclitaxel- (PTX-)
loaded PLGA NPs of ∼225.3nm in size. Using MCF-7 breast
cancer cells as a MUC1-overexpressing model, the aptamer
increased the uptake of nanoparticles into the target cells
as measured by ﬂow cytometry. Moreover, the PTX-loaded
Apt-NPs enhanced in vitro drug delivery and cytotoxicity
to MUC1+ cancer cells, as compared with nontargeted NP
lacking the MUC1 aptamer. The behavior of this novel
aptamer-NP bioconjugate suggests that MUC1 aptamers
may have a wider application potential in targeted gene
delivery towards MUC1-overexpressing tumors [66]. Other
aptamers used for targeted delivery of NP have included
PLGA conjugated to polyethylene glycol (PEG), which have
been used to deliver encapsulated prodrugs. PLGA NP are
targeted using aptamers with aﬃnity for the extracellular
domain of PSMA [67, 68]. Such NP are highly eﬃcacious
compared to prodrugs in vivo, and pharmacokinetic studies
showed improvements in tolerability and eﬃcacy compared
tostandardchemotherapy(Figure 10).Weenvisionthatsuch
a NP design might greatly enhance gene delivery targeted
speciﬁcally to prostate cancer cells expressing PSMA.
Other uses of aptamers have included a PLGA NP
of ∼156nm decorated with aptamer AS1411 (Apt-NP)Journal of Drug Delivery 15
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Figure 9: Targeted nanoparticles are promising for future in vivo gene delivery approaches. (a) PSMA-targeted PLGA-based microparticles
enterLNCaP(PSMA+)PCacells.Untreatedcontrol(1),after30minofexposuretonontargetedFITC-loaded(2),andtargetedFITC-loaded
(3) MBs. Cell nuclei were stained with Hoechst (blue). The number of green-positive cells per ﬁeld was signiﬁcantly diﬀerent from that of
nontargeted MBs. Reprinted from [64] with permission from American Chemical Society. (b) Confocal ﬂuorescent scanning microscopy
images detecting cellular uptake of MUC-1 targeted Aptamer conjugated NPs (top row) or NPs (bottom row) in MCF-7 cells. Green
ﬂuorescent FITC was encapsulated in Apt-NPs and NPs. The nuclei were stained blue with DAPI. The right column showed the merged
images of the FITC and the DAPI channels. MCF-7 cells were exposed to FITC-encapsulated Apt-NPs or NPs at 100μg/mL for 2 hours.
Reprinted from [66] under the terms of the Creative Commons Attribution License.
[69]. AS1411 is a DNA aptamer that speciﬁcally binds to
nucleolin, a protein upregulated in the plasmsa membrane
of both cancer cells and angiogenic blood vessels. Apt-
NP was used to facilitate antiglioma delivery of paclitaxel
(PTX). The Ap-nucleolin interaction signiﬁcantly enhanced
cellular association of nanoparticles in C6 glioma cells
and increased the cytotoxicity of its payload. Prolonged
circulation and enhanced PTX accumulation at the tumor
site were achieved by Ap-PTX-NP, which also yielded higher
tumor inhibition on C6 glioma xenografts and prolonged
survival when comapred to PTX-NP (untargeted) and Taxol.
Therefore, aptamer-functionalized PLGA NP can be an
eﬃcient therapeutic and this design might be adapted as well
for successful potential gene delivery to glioma.
Antibodies. Other PLGA NP that have been used for
eﬀective cellular targeting have included PLGA nanobubbles
(NB) for cancer targeting and imaging using optical and US
modalities. For example, PLGA NBs have been conjugated
with cancer-targeting ligands such as a humanized antibody
to target the overexpressed TAG-72 antigen [70]. NB-
assisted dual-mode imaging was demonstrated on a gelatin
phantom with multiple embedded tumor simulators at
diﬀerent NB concentrations, demonstrating the feasibility
of using dual-mode contrast agents for cancer targeting
and simultaneous ﬂuorescence/US imaging. Another PLGA-
PEG NP recently described coupled the J591 monoclonal
antibody to its surface in order to direct targeting towards
PSMA-expressing prostate cancer cells. A pDNA encoding
β-gal was complexed to this NP via a salicyl-hydroxamic-
acid- (SHA-) derivatized PEI. After encapsulation, an 8-
to 10-fold enhancement in gene expression was attained
due to enhanced speciﬁc internalization and uptake of the
complex in PSMA-expressing cells. The release of pDNA
from NP showed a small initial burst release followed by
a 5% release over 48h. The release accelerated thereafter
and ∼60% was released within a month. Also, the PEG-
PLGAcomposition (triblockpolymer) wasfoundtoenhance
the polyplex/microparticle localization to the cell nucleus
and this enhanced the endocytic process of J591-mediated
targeting in prostate cancer cells.
RGD. Another class of polymeric contrast agents with
targeting potential was described in which the Arg-Gly-Asp
(RGD) peptide sequence was conjugated to either PLA or
PLGA microcapsules [72, 73]. These hollow, biodegradable16 Journal of Drug Delivery
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Figure 10: Future Potential of PLGA-based nanoparticles for realizing eﬃcient in vivo drug delivery. (a) PLGA formulations for drug
delivery.TheantitumoreﬃcacyofsingleintratumoralinjectionsofdrugsorcontrolswascomparedforseveralNPgroups.Groupsexamined
included saline, pegylated PLGA NP (NP), Docatexel- (Dtxl-) encapsulated NP (Dtxl-NP) at 40mg/kg, or Dtxl-NP-PSMA targeted Aptamer
conjugates at 40mg/kg (Dtxl-NP-Apt). Aptamer-targeted NPs were more eﬃcacious in tumor reduction compared to control groups. Data
points labeled with “∗” were statistically signiﬁcant compared with all other groups by analysis of variance (ANOVA) at a 95% conﬁdence
interval. (b) Representative mice at the end point for each group are shown (left) alongside images of excised tumors (right). For the Dtxl-
NP-Aptgroup,whichachieved completetumorregression,thescartissueandunderlyingskinatthesiteofinjectionareshown.Blackarrows
point to the position of the implanted tumor on each mouse. Reprinted from [68] with permission from PNAS.
microcapsules targeted αvβ3a n dαvβ5 integrins, typically
expressed during angiogenesis. In vitro results indicated
that the modiﬁed capsules remained echogenic and adhered
speciﬁcally to the breast cancer cell line MDA-MB-231. An
interestingmodiﬁcationofthisapproachhasbeenutilization
of a cyclic RGD targeting moiety conjugated via a micelle-
type PLGA-4 arm-PEG branched polymer for detecting and
treating pancreatic cancer [74]. These NPs contained the
4-arm PEG as a corona and PLGA as a core, while the
particle surface was conjugated with cRGD for in vivo tumor
targeting. The hydrodynamic size of NP was ∼150–180nm
andNIRmicroscopyandﬂowcytometrystudiesshowedthat
the cRGD-conjugated NPs were taken up more eﬃciently
by U87MG glioma cells overexpressing integrins. Whole-
body imaging showed that the cRGD NP had the highest
accumulation in pancreatic tumors at 48h after-injection
with low in vivo toxicity. We would predict additional
receptor targeting will be attempted in the near future and
this will likely extend targeting of PLGA nanoparticles to the
VEGFR and EGFR family of receptors to achieve enhanced
drug and gene delivery, as already has been shown to work
for microbubbles targeting the VEGFR2 receptor in tumor-
associated endothelial cells [75, 76].
Proapoptotic. PLGA NPs coated with a proapoptotic
monoclonal antibody have been eﬃcient in delivering drugs
in a targeted manner. For example, use of NP coated with
Conatumumab or AMG 655 death-receptor 5 antibodies
(DR5-NP) has preferentially targeted DR5-expressing cells
and has induced apoptosis in a speciﬁc manner while also
delivering encapsulated drugs such as camptothecin [77].
This is an interesting example of antibody conjugation to
NP surface that can be exploited for the dual functions
of targeted drug delivery and cell killing. Another example
used gene delivery to achieve apoptosis in prostate tumors
by delivering pDNA expressing an shRNA against annexin
A2 [78]. In prostate cancer progression, annexin A2 is
upregulated cancer. These PLGA NP sustained intracellular
delivery of shRNA and achieved long-term downregulation
of annexin A2. Intratumoral administration of pDNA-
shAnxA2-loaded NP to xenograft prostate tumors in nude
mice inhibited tumor growth through reductions in annexin
A2 and VEGF levels. This interesting study suggests that the
use of sustained-release polymeric NP for delivering shRNA
constructs might serve as an eﬀective adjuvant treatment
option for cancer.
One important ﬁnal consideration for practical use of
PLGA or any NP for receptor and other tumor-targeted
genes delivery is the size range required for therapeutically
eﬀective drug concentrations at tumor sites while reducing
u n d e s i r a b l es i d ee ﬀects. For example, targeted drug delivery
using long-circulating particulate drug carriers of controlled
size (<100nm diameter) (reviewed in [79]) holds great
potential to improve the treatment of cancer by selectively
providing enhanced permeability and retention (EPR) and
optimal tumor distribution of NP.
4.3. Future Uses: Targeted Echogenic PLGA Nanoparticles for
Theranostic Applications. For future applications, echogenicJournal of Drug Delivery 17
PLGA NP will be important to achieving theranostic appli-
cations (diagnostic and therapeutic) for cancer. For example,
for early cancer diagnosis and therapy, new systems will be
continually designed and developed with key components
uniquely structured at nanoscale according to medical
requirements. For imaging, it is envisioned that quantum
dots with emissions in the near-infrared (NIR) range will
continue to be utilized for delivering drugs and/or nucleic
acids. For example, quantum dots have been successfully
conjugated onto a surface of a nanocomposite material
consisting of a spherical polystyrene matrix (<150nm).
Internally embedded supraparamagnetic Fe3O4 nanoparti-
cles (<10nm) could be successfully loaded with PTX onto
this nanocomposite material by using a layer of PLGA
[80]. Variations of such a nanocarrier were then successfully
conjugated to antibodies or aptamers to achieve cell-speciﬁc
targeting. For example, these PTX-loaded PLGA nanocarri-
ers were conjugated to an anti-PSMA antibody for targeting
of LNCaP prostate tumors with high speciﬁcity in vivo.
For diagnostic applications, we envision that nanoparticle
contrast agents will become of increasing interest for high-
resolution imaging in medicine. For example, a novel dual-
modal contrast agent has been developed for structural
and functional imaging of cancer [81]. This contrast agent
was fabricated by encapsulating indocyanine green (ICG) in
PLGA MB. The technical feasibility of concurrent structural
andfunctionalimagingwasdemonstratedthroughaseriesof
tests in which an aqueous suspension of ICG-PLGA MB was
injected into a transparent tube embedded in an Intralipid
phantom at diﬀerent ﬂow rates and concentrations. Concur-
rent ﬂuorescence imaging and B-mode ultrasound imaging
successfully captured the changes of microbubble ﬂow rate
and concentration with high linearity and accuracy. One
potential application of the proposed ICG-PLGA MB would
be for the identiﬁcation and characterization of peritumoral
neovasculature. Enhanced coregistration between tumor
structural and functional boundaries could be achieved
using US-guided near-infrared diﬀuse optical tomography.
In a similar manner, photoacoustic imaging applications
also will be implemented, for example, NP exhibiting a
near-infrared (NIR) absorption can be prepared by incor-
poration of ICG into PLGA [61, 62]. These NPs were
biocompatible in vitro and had a high NIR dye encapsulation
eﬃciency (>98%) and two diﬀerent size fractions were
obtained of ∼640nm and ∼390nm. Cytotoxicity studies
indicated no changes in metabolic activity, proliferation,
or membrane integrity. Their high optical absorption at
∼800nm in combination with absence of cytotoxicity
qualiﬁes the ICG-PLGA particles as promising candidates
for degradable photoacoustic contrast agents in future
studies.
Other nanoparticles in development include composite
PLGA-magnetic particles for simultaneous drug delivery and
imaging [82], and these might also be applied to gene
deliveryinfutureapplications.Thesemagneticnanoparticles
were embedded in PLGA matrices (PLGA-MNP) to achieve
a dual-drug delivery and imaging system and were capable
of encapsulating both hydrophobic and hydrophilic drugs
in a 2:1 ratio while retaining favorable biocompatibility
and cellular uptake properties. For targeted delivery of
drugs, targeting ligands such as Herceptin were tested,
demonstrating enhanced cellular uptake. Also, magnetic
resonance imaging was used to show improved contrast by
PLGA-MNP compared to commercial contrast agents due
to higher T2 relaxivity with a blood circulation half-life of
∼47min in a rat model. These PLGA-based matrices may be
applied to both imaging and adapted to achieve successful
gene delivery.
5. Conclusions
PLGA and other nanoparticle delivery systems in general
have distinct advantages for gene delivery, such as protecting
DNA from degradation and enhancing complex stability.
PLGA-based NPs can penetrate deeply into tissues through
ﬁne capillaries and are generally taken up eﬃciently by cells.
This allows eﬃcient delivery and accumulation of therapeu-
tic agents, such as conventional medicines, vaccine antigens,
proteins, and genes, to target sites (tissues or organs) in
the body. PLGA NPs also have the advantage of sustained
and controlled release of the encapsulated therapeutic agent
over a period of days to several weeks compared with
natural polymers, which have a relatively short duration
of drug release. PLGA and other NP, if synthesized in a
manner to render acoustic activity, can strongly promote not
only therapy delivery but also serve as contrast agents for
standard US-mediated imaging or photoacoustic imaging.
PLGA NP will continue to be reﬁned and improved also to
target gene and drug delivery to certain cells and tissues via
conjugation of highly speciﬁc antibodies, aptamers, or other
molecules to their surface. For gene delivery, other nucleic
acid types will be expanded either loaded onto or into PLGA
NP, including promising directions using siRNA/miRNA
technology to silence multiple tumor-promoting genes, for
example.
Overall, the promise of these technologies and ap-
proaches using PLGA NPs represents a novel and poten-
tially more eﬀective means to manage cancer and other
diseases. However, thorough evaluation for pharmacoki-
netics, biodistribution, toxicity, and eﬃcacy of particular
therapeutic agents (gene or drugs) is still required before
widespread use will be achieved for PLGA NP in clinical
trials. Nevertheless, gene delivery using PLGA- or PLGA-
based polymers is an attractive area with vast opportunities
for biomedical research. During the past few years, research
on PLGA NP has increased in the ﬁeld of drug delivery
and targeting of NP to cancer cells or blood vessels within
tumors. We predict these improvements also may promote
advancesinthegenedeliveryapplicationsofPLGANP.These
polymers are increasingly becoming feasible candidates for
delivering nucleic acids as anticancer agents and for vaccine
immunotherapy. We also believe that PLGA-based NP will
be developed further to enable treatment and diagnosis of
a variety of other diseases besides cancer. Therefore, our
predictionsarethatPLGA-relatedNPtechnologyshouldplay
increasingly more important and mainstream roles in tissue
engineering and in other emerging areas such as stem cell
research.18 Journal of Drug Delivery
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